Original paper
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
Volume: 36, Issue: 9, Pages: 1616 - 1628
Published: Jun 1, 2021
Abstract
Background Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD). Methods This randomized, open-label, active-controlled Phase 3 study compared roxadustat versus darbepoetin alfa (DA) in non-dialysis-dependent (NDD) CKD patients with anaemia for ≤104 weeks. Doses were titrated to correct and maintain haemoglobin (Hb) within 10.0–12.0...
Paper Details
Title
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)
Published Date
Jun 1, 2021
Volume
36
Issue
9
Pages
1616 - 1628
TrendsPro
You’ll need to upgrade your plan to Pro
Looking to understand a paper’s academic impact over time?
- Scinapse’s Citation Trends graph enables the impact assessment of papers in adjacent fields.
- Assess paper quality within the same journal or volume, irrespective of the year or field, and track the changes in the attention a paper received over time.
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.